Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

(±)-Ibipinabant

((±)-SLV319; (±)-BMS6462) Cat. No.: HY-14791A

(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (**CB-1**) receptor antagonist with an IC_{50} of 22 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

2-Arachidonoylglycerol

Cat. No.: HY-W011051

2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg (26.4 mM * 100 μL in Acetonitrile),

6-Iodopravadoline

(AM630) Cat. No.: HY-15421

6-Iodopravadoline (AM630) is a selective CB_2 antagonist with K_i of 31.2 nM, and displays 165-fold selectivity over CB_1 receptors.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

A-836339

Cat. No.: HY-12761

A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

AM251

Cat. No.: HY-15443

AM251 is a selective **cannabinoid 1** (**CB1**) receptor antagonist with an IC_{50} of 8 nM, also acts as a potent **GPR55** agonist with an EC_{50} of 39 nM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM9405

Cat. No.: HY-112707

AM9405 is a novel peripherally active **cannabinoid type 1 (CB1)** and **serotonin type 3 receptor** agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC_{50}s of 45.71 and 0.076 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anandamide

Cat. No.: HY-10863

Anandamide is an immune modulator in the central nervous system acts via not only **cannabinoid receptors** (**CB1** and **CB2**) but also other targets (e.g., **GPR18**/**GPR55**).



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY 38-7271

Cat. No.: HY-119744

BAY 38-7271 is selective and highly potent and cannabinoid **CB_1/CB_2 receptor** agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB_1 receptor and CB_2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay 59-3074

Cat. No.: HY-100488

Bay 59-3074 is a selective cannabinoid **CB_1/CB_2 receptor** partial agonist with K_i values of 48.3 and 45.5 nM at human CB_1 and CB_2 receptors, respectively. Bay 59-3074 has analgesic properties.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BML-190

(Indomethacin morpholinylamide; IMMA) Cat. No.: HY-15420

BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CB1 antagonist 1

Cat. No.: HY-U00397

CB1 antagonist 1 is an antagonist of **CB1 receptor**, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB1 antagonist 2

Cat. No.: HY-116649

CB1 antagonist 2 is caimabinoid 1 (**CB1**) antagonist extracted from patent WO2016184310A1, compound 3, inhibits CB1 in vivo with an IC_{50} of 25.5 nM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CB1 inverse agonist 1

Cat. No.: HY-135280

CB1 inverse agonist 1 is a highly potent, orally active, and specific inverse agonist of **CB1 receptor** with IC_{50}s of 7.5 nM and 4100 nM for **CB1** and **CB2 receptors**, respectively. Anorexigenic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB1-IN-1

(BPRCB1184)

Cat. No.: HY-12790

CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CB2 modulator 1

Cat. No.: HY-135419

CB2 modulator 1 (compound 130) is a potent **CB2** modulator. CB2 modulator 1 has the potential for immunedisorders, inflammation, osteoporosis, renal ischemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2R-IN-1

Cat. No.: HY-100328

CB2R-IN-1 is a potent **cannabinoid CB_2** receptor inverse agonist with a K_i of 0.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW842166X

Cat. No.: HY-14167

GW842166X is a potent and selective **cannabinoid receptor 2** (CB2) agonist with IC_{50} values of 63 and 91 nM for human and rat CB2, respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

JD-5037

Cat. No.: HY-18697

JD-5037 is a novel, peripherally restricted **CB_1R** antagonist with an IC_{50} of 1.5 nM.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Leelamine hydrochloride

Cat. No.: HY-110028

Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

LY2828360

Cat. No.: HY-16642A

LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid **(CB_2)** agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MDA 19

Cat. No.: HY-15451

MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

N-Oleoyl glycine

Cat. No.: HY-113204

N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of **CB1 receptor** and **Akt** signaling pathway in 3T3-L1 adipocyte.



Purity: >99.0%
Clinical Data:
Size: 10 mM × 1 mL, 10 mg

O-2050

Cat. No.: HY-133533

O-2050 is a high affinity **cannabinoid CB_1 receptor** silent antagonist. O-2050 also acts as a partial agonist in inhibiting forksolin-induced cyclic AMP stimulation (EC_{50}=40.4 nM). O-2050 antagonizes effects of CP-55940 in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olivetol

Cat. No.: HY-W008364

Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors **CB1** and **CB2**. Olivetol also inhibits **CYP2C19** and **CYP2D6** activity, with IC_{50}s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Olorinab

(APD 371)

Cat. No.: HY-111110

Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (**CB_2**) agonist, with an **EC_{50}** of 6.2 nM for hCB_2.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

OMDM-6

Cat. No.: HY-135882

OMDM-6 is a hybrid agonist of **vanilloid receptor type 1 (VR1, TRPV1)** (EC_{50}=75 nM) and **cannabinoid receptor type 1 (CB1)** (K_i=3.2 μM). OMDM-6 inhibits **anandamide cellular uptake (ACU)** with a **K_i** of 7.0 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Org 27569

Cat. No.: HY-13288

Org 27569 is a potent **CB1 receptor** allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Otenabant

(CP-945598)

Cat. No.: HY-10871

Otenabant is a potent and selective **cannabinoid receptor CB1** antagonist with **K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Otenabant Hydrochloride

(CP 945598 Hydrochloride)

Cat. No.: HY-10871A

Otenabant Hydrochloride is a potent and selective **cannabinoid receptor CB1** antagonist with **K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pregnenolone

(3β-Hydroxy-5-pregnen-20-one)

Cat. No.: HY-B0151

Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Pregnenolone monosulfate

(3β-Hydroxy-5-pregnen-20-one monosulfate) **Cat. No.:** HY-B1739

Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pregnenolone monosulfate sodium salt

(3β-Hydroxy-5-pregnen-20-one monosulfate sodium salt) **Cat. No.:** HY-110189

Pregnenolone monosulfate sodium salt (3β-Hydroxy-5-pregnen-20-one monosulfate sodium salt) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Rimonabant

(SR141716) **Cat. No.:** HY-14136

Rimonabant (SR141716) is a highly potent, brain penetrated and selective central **cannabinoid receptor (CB1)** antagonist with a K_i of 1.8 nM. Rimonabant (SR141716) also inhibits **Mycobacterial membrane protein Large 3 (MMPL3)**.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Rimonabant Hydrochloride

(SR 141716A Hydrochloride) **Cat. No.:** HY-14137

Rimonabant hHydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central **cannabinoid receptor (CB1)** antagonist with an K_i of 1.8 nM.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RVD-Hpα

Cat. No.: HY-P1397

RVD-Hpα is the N-terminally extended form of human hemopressin that acts as a selective **CB1 receptor** agonist. RVD-Hpα increases intracellular Ca^{2+} levels in cells expressing CB1 receptors in vitro. RVD-Hpα also high affinity CB2 positive allosteric modulator (K_i=50 nM).

RVDPVNFKLLSH

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RVD-Hpα TFA

Cat. No.: HY-P1397A

RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective **CB1 receptor** agonist. RVD-Hpα TFA increases intracellular Ca^{2+} levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

RVDPVNFKLLSH

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR144528

Cat. No.: HY-13439

SR144528 is a potent and selective **CB2 receptor** antagonist with a K_i of 0.6 nM.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taranabant

(MK-0364) **Cat. No.:** HY-10013

Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.



Purity: 99.28%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Taranabant ((1R,2R)stereoisomer)

(MK0364 (1R,2R)stereoisomer) **Cat. No.:** HY-10013B

Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Taranabant racemate

(MK-0364 racemate) **Cat. No.:** HY-10013A

Taranabant racemate is an antagonist and/or inverse agonist of the **Cannabinoid-1** (**CB1**) **receptor** extracted from patent WO 2004048317 A1.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tedalinab
(GRC-10693)

Cat. No.: HY-14900

Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 **(CB2)** agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TM38837

Cat. No.: HY-112340

TM38837 is a peripheral selective **cannabinoid receptor type 1 (CB1)** receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VCE-004.8

Cat. No.: HY-128872

VCE-004.8, a semi-synthetic multitarget cannabinoquinoid, is a specific **PPARγ** and **CB_2** receptor dual agonist with potent anti-inflammatory activity. VCE-004.8 inhibits **prolyl-hydroxylases (PHDs)** and activates the **HIF** pathway.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Voacamine

Cat. No.: HY-N6932

Voacamine, an indole alkaloid, isolated from Voacanga Africana, exhibits potent **cannabinoid CB1 receptor** antagonistic activity. Voacamine also inhibits **P-glycoprotein** (**P-gp**) action in multidrug-resistant tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

WIN 55,212-2 Mesylate
((R)-(+)-WIN 55212)

Cat. No.: HY-13291

WIN 55,212-2 Mesylate is a potent aminoalkylindole **cannabinoid (CB) receptor** agonist with K_is of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Yangonin

Cat. No.: HY-N0919

Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an IC_{50} and a K_i of 1.79 ± 0.53 μM and 0.72±0.21 μM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

β-Caryophyllene ((-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene)

Cat. No.: HY-N1415

β-Caryophyllene is a **CB2 receptor** agonist.



Purity: >94.0%
Clinical Data: No Development Reported
Size: 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com